AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Biology & Therapy

• Publication date

  2012-06-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cbt.20563PMID 22669575PMCID PMC3679100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proapoptotic Protein Smac Mediates Apoptosis in Cisplatin-resistant Ovarian Cancer Cells When Treated with the Anti-tumor Agent AT101*

  2011cited by this paper
• A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

  2011cited by this paper
• Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.

  2010cited by this paper
• Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.

  2010cited by this paper
• Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells.

  2010cited by this paper
• XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.

  2009cited by this paper
• Merlin is a potent inhibitor of glioma growth.

  2008cited by this paper
• Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo

  2008cited by this paper
• SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.

  2008cited by this paper
• Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin

  2007cited by this paper
• XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics

  2007cited by this paper
• A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.

  2007cited by this paper
• XIAP Is Related to the Chemoresistance and Inhibited Its Expression by RNA Interference Sensitize Pancreatic Carcinoma Cells to Chemotherapeutics

  2006cited by this paper
• Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.

  2006cited by this paper
• Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.

  2005cited by this paper
• Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

  2005cited by this paper
• Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells

  2005cited by this paper
• Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.

  2004cited by this paper
• Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.

  2003cited by this paper
• The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells

  2002cited by this paper
• Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.

  2000cited by this paper
• Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.

  2000cited by this paper
• Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.

  2000cited by this paper
• Screening for ovarian cancer: a systematic review.

  1998cited by this paper
• Cancer of the ovary.

  1994cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper

• Discovery, preclinical safety, and efficacy characterization of SMAC mimetic S-016-1348 as a potential cancer therapeutic.

  2026cites this paper
• IAPs in cancers: molecular mechanisms, clinical prognostic value, and translational therapeutic potential

  2026cites this paper
• A Comprehensive Insight into Apoptosis: Molecular Mechanisms, Signaling Pathways, and Modulating Therapeutics

  2025cites this paper
• Anticancer Effects of Combined Blue Light and Ionizing Irradiation

  2025cites this paper
• The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution

  2025cites this paper
• Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin.

  2024cites this paper
• Study on the sensitizing effect of SM-1 combined with irradiation on head and neck squamous cell carcinoma

  2024cites this paper
• Research Progress in the Use of Small Molecule Smac Mimetics in Combination Therapy of Cancer.

  2024cites this paper
• Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.

  2024cites this paper
• Understanding and targeting resistance mechanisms in cancer

  2023cites this paper
• Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?

  2023cites this paper
• The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP

  2023cites this paper
• The GSTP1/MAPKs/BIM/SMAC modulatory actions of nitazoxanide: Bioinformatics and experimental evidence in subcutaneous solid Ehrlich carcinoma-inoculated mice.

  2023cites this paper
• A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer

  2022cites this paper
• Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist

  2022influential citation
• Combined modality including novel sensitizers in gynecological cancers

  2022cites this paper
• Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.

  2022cites this paper
• The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer

  2022cites this paper
• Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

  2021cites this paper
• Therapeutics Targeting the Core Apoptotic Machinery

  2021cites this paper
• Biomaterial-based drug delivery systems used to improve chemotherapeutic activity of pharmaceuticals and to target inhibitors of apoptosis proteins

  2020cites this paper
• Smac peptide and doxorubicin-encapsulated nanoparticles: design, preparation, computational molecular approach and in vitro studies on cancer cells

  2020cites this paper
• Combination Therapy Using Smac Peptide and Doxorubicin-encapsulated MUC 1-targeted Polymeric Nanoparticles to Sensitize Cancer Cells to Chemotherapy: An in vitro and in vivo Study.

  2020cites this paper
• Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.

  2020cites this paper
• The Strong Inhibitory Effect of Combining Anti-Cancer Drugs AT406 and Rocaglamide with Blue LED Irradiation on Colorectal Cancer Cells.

  2020cites this paper
• Future Therapeutic Directions for Smac-Mimetics

  2020influential citation
• The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice

  2020cites this paper
• Anti-apoptotic proteins in the autophagic world: an update on functions of XIAP, Survivin, and BRUCE

  2020cites this paper
• The effect of DEBIO 1143 usage alone or in combination with Tamoxifen on estrogen receptor positive breast cancer cell lines.

  2020cites this paper
• Tamoxifen - DEBIO 1143 kombinasyonunun östrojen reseptörü pozitif meme kanseri hücre hatlarındaki etkisi.

  2020cites this paper
• Therapeutic Inducers of Apoptosis in Ovarian Cancer

  2019cites this paper
• WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway

  2019cites this paper
• Aryl-fluorosulfate-based Lysine Covalent pan-Inhibitors of Apoptosis Proteins (IAP) Antagonists with Cellular Efficacy.

  2019cites this paper
• New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer

  2018cites this paper
• DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death

  2018cites this paper
• Molecular Designing of Small-Molecule Inhibitors for Apoptosis Regulation

  2018cites this paper
• Regulating the Master Regulator: Controlling Ubiquitination by Thinking Outside the Active Site.

  2017cites this paper
• Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.

  2017cites this paper
• Genetic visualization of protein interactions harnessing liquid phase transitions

  2017cites this paper
• Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)

  2017influential citation
• IAPs protect host target tissues from graft-versus-host disease in mice.

  2017cites this paper
• IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis

  2016cites this paper
• FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases

  2016cites this paper
• ApoCanD: Database of human apoptotic proteins in the context of cancer

  2016cites this paper
• In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP.

  2015cites this paper
• Apoptosis and Autophagy: The Yin–Yang of Homeostasis in Cell Death in Cancer

  2015cites this paper
• Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.

  2015cites this paper
• The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.

  2015cites this paper
• Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

  2015cites this paper
• AT-406, an IAP inhibitor, activates apoptosis and induces radiosensitization of normoxic and hypoxic cervical cancer cells.

  2014cites this paper
• Targeting the apoptosis pathway in hematologic malignancies

  2014cites this paper
• Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro.

  2014cites this paper
• Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.

  2014cites this paper
• The versatile roles of CARDs in regulating apoptosis, inflammation, and NF-κB signaling

  2014cites this paper
• X-Linked Inhibitor of Apoptosis Protein – A Critical Death Resistance Regulator and Therapeutic Target for Personalized Cancer Therapy

  2014cites this paper
• Molecular Pathways Molecular Pathways : Turning Proteasomal Protein Degradation into a Unique Treatment Approach

  2014cites this paper
• Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma

  2014cites this paper
• Manipulating the apoptotic pathway: potential therapeutics for cancer patients.

  2013cites this paper
• Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation

  2013cites this paper
• Apoptosis in Cancer: Mechanisms, Deregulation, and Therapeutic Targeting

  2013cites this paper
• IAP proteins as targets for drug development in oncology

  2013cites this paper